Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith Zaslavsky, CEO of Ignite Proteomics and IMAC Holdings. “Our analysis shows ...
Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback